Official announcements
Recall
|
Medicines
|
16/12/2016
In a letter dated December 13, 2016, the marketing authorization holder informed its customers that the above-mentioned batches of "Sertraline Sandoz" and "Lamotrigine Sandoz" are being recalled. During the routine incoming goods inspection on the…
Safety warnings
|
messages in brief
|
14/12/2016
Stem cell and other cell therapies are associated with great hopes, both among physicians and patients. Great progress is expected, especially in the treatment of difficult-to-treat and chronic diseases. For this very reason, however, it is…
Recall
|
Veterinary Medicines
|
06/12/2016
The marketing authorization holder has informed its supplied customers in a letter dated November 30, 2016, that stability tests have revealed a reduced rabies antigen content after 15 months of storage. Therefore, the above mentioned batch of this…
messages in brief
|
30/11/2016
EU Regulation 536/2014 is expected to standardize the approval procedure for clinical trials throughout the EU from fall 2018. These are an essential part of drug development and, not least, provide objective proof of the effect and side effects of…
messages in brief
|
07/11/2016
AGES Medical Market Surveillance launches a social media campaign from November 7 - 11, 2016 to increase willingness to report adverse reactions. Vienna (OTS) - In addition to positive effects, medicinal products can also have potential side effects.…
messages in brief
|
02/11/2016
Legal trade in pharmaceutical specialties via the Internet was made possible in Austria in 2015 by an amendment to the Austrian Medicines Act and linked to legal requirements. Technical features on the drug provider's website enable consumers to…
Safety warnings
|
Blood & Tissue
|
28/10/2016
European Union/European Economic Area (EU/EEA)Member States should consider a range of mitigation measures regarding the Zika virus epidemic
Recall
|
Medicines
|
24/10/2016
The marketing authorization holder informed its supplied customers in a letter dated October 12, 2016, that an impurity, "lmpurity D", was detected in the course of stability tests, which in the measured concentration does not indicate any health…
Recall
|
Medicines
|
24/10/2016
The marketing authorization holder informed its supplied customers in a letter dated October 13, 2016, that an impurity, "lmpurity D", was detected during stability tests. In the measured concentration there is no health risk for the patients. A…
Safety warnings
|
Blood & Tissue
|
24/10/2016
The Federal Office for Public Health Safety has been informed by the Italian authority that WNV NAT testing will now be carried out in the province of Oristano (Region of Sardinia) in addition to the regions already announced.